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Introduction
Analyzing genomic and health data across populations is
central to understanding the involvement of genetic fac-
tors in health and disease.1,2 Responsible data sharing sup-
ported by trustworthy data governance can support the
equitable delivery of genomic medicine and the right of
everyone to benefit from scientific research.3,4
The success of data sharing relies on public support and
trust.5 Collecting and sharing data brings to the forefront
issues of privacy and questions about exploitation and un-
even global distributions of scientific resources, both past
and present.6 Data sharing should therefore be accompa-
nied by an understanding of how members of the public,
as donors of data, see and support the process of data
sharing.1 For example, there is public hesitancy about con-
nections between public and for-profit sectors in genomic
and health research.7–11 However, research into public per-
ceptions of genomics and biomedical data is dominated by
studies from Europe and North America and rarely enables
comparative study.6,7,12,13
This paper presents findings from a study of public per-
spectives on genomic data sharing, drawing on responses
from 36,268 individuals across 22 countries and gathered
in 15 languages. The objective of the study is to explore
global public attitudes toward willingness to donate one’s
DNA and health information to be shared for research
(both non-profit and for-profit), together with an under-
standing of the factors that shape this. The study offers
insight for policy makers, genomic researchers, clini-
cians, and governments who are implementing genomic
research strategies across the world. First, we examine
how the willingness to donate DNA and health informa-
tion differs depending on with whom data are shared,
comparing the willingness to donate to medical, non-
profit, and for-profit groups across countries. Second,
we examine how this willingness to donate is shaped
by several factors. One factor is one’s familiarity with
DNA, genetics, and genomics—either through popular
culture, media, education, personal experience due to be-
ing a genetics patient or having a family history of dis-
ease, or working as a genetic health professional or ge-
netic scientist. We grouped ‘‘DNA, genetics, and
genomics’’ into one concept in the question about famil-
iarity in our survey so that participants could see that the
terms were linked, even if they had only heard of one of
them, and we summarize this in the Results as ‘‘familiar-
ity with genetics.’’ A second factor is one’s beliefs about
genomic data’s being different from other health data
(cf. ‘‘genetic exceptionalism’’). A third factor is one’s trust
in organizations involved in the collection, sharing, and
use of data.14–16
In this paper we use the term ‘‘genomics’’ generically as a
descriptor of any level of DNA testing/analysis/interpreta-
tion. In the survey itself, we used the term ‘‘DNA informa-
tion’’ instead of ‘‘genomic data’’ (a term more commonly
used in scientific circles) because our pilot work showed744 The American Journal of Human Genetics 107, 743–752, Octobe‘‘DNA’’ was better understood than ‘‘genetics’’ or
‘‘genomics.’’Material and Methods
Sample
Via the international network of researchers within the Global
Alliance for Genomics and Health (GA4GH), the research team
invited social science, genetic counselling, and policy collabora-
tors around the world to participate in the ‘‘Your DNA, Your Say’’
project through either supporting recruitment into the project
or translating the survey into their native language. The ‘‘conve-
nience’’ mix of countries involved in the final dataset thus reflects
the reach of the GA4GH network and enthusiasm to participate in
the research; all collaborators are listed as co-authors, and eachwill
explore, in time, their own individual country data in more depth
in future publications (see Video S1 for details about the project
and translations). Data were collected via a cross-sectional online
survey with participants recruited via the market research com-
pany Dynata. We aimed to recruit a sample that was as representa-
tive as possible of each country’s population with regard to gender,
age, and education level. To this end, participant characteristics
were monitored during recruitment to proactively ascertain indi-
viduals from under-represented population subgroups. Sociode-
mographic characteristics of participants from each country are
shown in Table S1.
In Japan, participants were recruited through a survey research
company (Cross Marketing) via the same approach. In Pakistan
and India, recruitment was conducted by market research com-
panies (Foresight and Maction, respectively) and methods were
varied to account for lower internet access. In Pakistan, partici-
pants completed the questionnaire on a tablet at a central loca-
tion. In India, participants completed the questionnaire on tablets
provided by field researchers. Completed surveys were gathered
from Argentina, Australia, Belgium, Brazil, Canada, China, Egypt,
France, Germany, India, Italy, Japan, Mexico, Pakistan, Poland,
Portugal, Russia, Spain, Sweden, Switzerland, the United
Kingdom, and the United States of America. Participants were
paid a small financial reward (<£1) for participating, and because
of the nature of recruitment, there are no details on non-response
rate. The study methodology, design, recruitment strategy, and
process of data collection are described separately.17
Measures
Our online survey contains 29 questions; background information
about the landscape of genomic research and data sharing is pro-
vided via nine films that sit within the survey (see Video S2 for
one of the films with Japanese subtitles), and no prior knowledge
about genomics is required to participate. Details on the survey,
data cleaning, and derivation of ‘‘familiarity with genetics’’ and
‘‘genetic exceptionalism’’ used in the analyses are provided in
the Supplemental Material and Methods.
Trust
Participants were asked to indicate if they would trust the
following people or institutions with their DNA or health informa-
tion: ‘‘my medical doctor,’’ ‘‘any medical doctor in my country,’’
‘‘any researcher at a university in my country,’’ ‘‘any researcher
in a company in my country,’’ and ‘‘the government of my
country.’’
Response options were ‘‘I would generally trust,’’ ‘‘I’m just not
sure,’’ and ‘‘I would not generally trust.’’ Variables were combinedr 1, 2020
to create a single binary indicator of whether people reported
trusting at least two of these people or organizations. Prior analysis
has found that many people trust their own doctor but are less
trusting of others.16 This binary variable aimed to capture trust
across users of health and genomic data.Analysis
Sample Description
Sample characteristics were summarized with standard descriptive
statistics. Bivariate relationships were evaluated with c2 tests
because all variables were categorical. The importance of p values
was considered in the context of multiple testing.
Meta-Analysis
We used meta-analysis to investigate relationships between
different sets of predictors and outcomes. This approach provides
an estimate of the association between variables for the whole
sample while also allowing exploration of between-country varia-
tion. For our outcomes, we used four measures of willingness to
donate DNA and medical information related to recipient: (a)
medical doctors, (b) non-profit researchers, (c) for-profit re-
searchers, and (d) more than one of these recipients. We examined
associations with three predictors (Table S3): (a) genetics familiar-
ity, (b) genetic exceptionalism, and (c) trust in the organizations
receiving the data. Analyses were adjusted for sociodemographic
variables (age, gender, having children, tertiary education, and
religiosity). For meta-analysis purposes, the three-category willing-
ness to donate variables were split into two binary contrasts: un-
sure versus unwilling to donate and unsure versus willing to
donate. This enabled us to compare participants who had a strong
position with those who were unsure.
We conducted a ‘‘two-step’’ individual participant data meta-
analysis to examine the relationship between the predictors
and outcomes.18,19 We used a random-effects model in all ana-
lyses because we anticipated between-country differences; we
estimated Cochrane’s Q and I2 values to test for the presence of
heterogeneity. Because of the nature of the data collection
approach, missing data were very limited (<5% for all questions),
and therefore, complete case analyses were conducted. Results
were tabulated and displayed with forest plots. All tests were
two-tailed. We present and interpret p values as measures of the
strength of evidence for an association rather than simply
applying a threshold for statistical significance.20 Analyses were
conducted in the R statistical software with the meta and metafor
packages.21–23 Further details are provided in the Supplemental
Material and Methods.
Ethics Approval
The online project is physically based at the Wellcome Genome
Campus, and all data are collected and stored in encrypted files
at theWellcome Sanger Institute in Cambridge. As part of the con-
ditions of research delivery at this research institution, the project
passed ethical review by the legal counsel as well as the Human
Materials and Data Management Committee to ensure that it
was compliant with appropriate ethical and legal standards for
participant involvement, data collection, and storage. Because
the online survey is fully anonymous (and even IP addresses are
not stored or shared with the research team), participants are
informed that their consent is given when they choose to click
off the landing page and start answering the questions. On the
landing page, the purpose of the project is explained as well as
what participation involves, and participants have a choice at
any stage within the survey to stop answering the questions andThe Americawithdraw. This ethics approval was sufficient to cover recruitment
into the online survey for most of the collaborators attached to the
project. The exception was Australia, where the University of Tas-
mania required an additional local REC process to be completed
plus the addition of their own separate consent form onto the
landing page of the survey for Australian participants only.Results
Sample Characteristics
After data cleaning, the analysis sample included 36,268
participants from 22 countries: Argentina (919), Australia
(1,212), Belgium (544), Brazil (1,349), Canada (2,966),
China (3,008), Egypt (1,427), France (790), Germany
(1,193), India (482), Italy (1,229), Japan (4,748), Mexico
(1,347), Pakistan (925), Poland (2,904), Portugal (2,224),
Russia (1,075), Spain (1,272), Sweden (821), Switzerland
(333), the United Kingdom (3,407), and the United States
of America (2,093). Sociodemographic characteristics of
each country sample, unadjusted results, and details of
data cleaning are provided in the Supplemental Material
and Methods.
Willingness to Donate to Different Groups
The majority of participants in the aggregate were either
unwilling or unsure about donating their anonymous
DNA and medical information for use by researchers
(Figure 1, Table S2, Figures S3 and S4).
In general, participants were most willing to donate
when the recipient was specified as a medical doctor and
least willing to donate when the recipient was a for-profit
researcher, but there were exceptions to this pattern
(Figure 1, Table S2, Figures S1–S4). For example, partici-
pants in Poland, Portugal, and Germany were considerably
less willing to donate to for-profit users than doctors,
whereas the difference was smallest in Egypt, India, and
Pakistan.
Within the survey glossary, we explained ‘‘anony-
mous’’ in more detail as follows: ‘‘removal of personal in-
formation such as name and date of birth. It is question-
able as to whether DNA information can ever be truly
anonymous as our DNA code is unique to us and thus,
in itself, could be used to identify us. However, in the cir-
cumstances we are exploring here, by making DNA and
medical information ‘anonymous,’ we mean detaching
personal identifiers from it.’’ What we actually mean
here is ‘‘de-identified,’’ but within the pilot work for
the survey, we discovered that public participants did
not naturally understand this term and ‘‘anonymous’’
was more easily understood. Thus, we added the glossary
definition within the survey itself to explain this in more
detail.
Genetics Familiarity
Familiarity with the concepts of DNA, genetics, and geno-
mics (summarized as ‘‘familiarity with genetics’’) varies by
country (Figure 2), however, the majority of participants inn Journal of Human Genetics 107, 743–752, October 1, 2020 745
Figure 1. Willingness to Donate Anonymous DNA and Medical Information to Different Recipient Groups, Stratified by Country
Each bar shows the percentage of the sample for each country reporting willingness to donate to a particular recipient. The colors of the
bars indicate the type of recipient—medical doctors, non-profit researchers, or for-profit researchers.most countries say that they are unfamiliar (total sample:
64.2%; Table S2), and only 35.8% of the total sample say
that they have some familiarity with the concepts,
including having personal experience of genetics (either
through being a patient with a genetic condition, having
a family history of a genetic condition, or working with
such patients).Genetic Exceptionalism
Overall, 53% of the sample viewed DNA as being different
from other types of medical information, but views on this
differed substantially between countries. For example, over
65% of participants in Mexico and Italy viewed DNA as be-Figure 2. Familiarity with Genetics (Including Familiarity Gained t
Each bar shows the percentage of the sample for each country report
resents a different self-reported level of familiarity—unfamiliar, conc
through being a patient with a genetic condition).
746 The American Journal of Human Genetics 107, 743–752, Octobeing different from other types of medical data, whereas
only 31% of those in Russia did (Figure 3, Table S2).Trust
Less than half the overall sample reported trusting multiple
users (doctors, non-profit researchers, commercial re-
searchers, governments, etc.)with theirDNAorhealth infor-
mation (Table S2). However, there was substantial variation
betweencountries in termsof trust:more than50%ofpartic-
ipants in China, India, the United Kingdom, and Pakistan
trusted more than one actor, compared to fewer than 30%
of participants in Egypt, Russia, Germany, and Poland
(Figure 4).hrough Personal Experience), Stratified by Country
ing level of familiarity with genetics/genomics. Each bar color rep-
eptual familiarity, or familiarity through personal experience (e.g.
r 1, 2020
Figure 3. Perception of DNA as Being Different from Other Medical Information (Genetic Exceptionalism) versus DNA as Being the
Same (or Unsure), Stratified by Country
Each bar shows the percentage of the sample who reported viewing DNA as different to other types of medical information or the per-
centage who viewed it as being the same or were unsure.Meta-Analyses
Familiarity with Genetics and Willingness to Donate
We found that familiarity with the concepts of DNA, ge-
netics, and genomics (termed ‘‘familiarity with genetics’’) is
associated with willingness to donate DNA and medical in-
formation. The association, adjusted for sociodemographic
factors, is shown in Figure 5. There was evidence for be-
tween-country heterogeneity (I2¼ 48% and I2¼ 61% for fa-
miliarity with genetics and personal experience, respec-
tively). Compared to participants who were unfamiliar
with genetics, thosewhowere familiar orhadpersonal expe-
riencehadgreater odds of beingwilling to donate (odds ratio
[OR]¼ 1.85, 95%CI¼ 1.11–2.00;OR¼ 2.70, 95%CI¼ 2.37–
3.09, respectively). The overall pattern of results was similar
when considering single groups of recipients of donated
DNA and medical information (doctors, non-profit re-
searchers, for-profit researchers); shown in Figures S5–S7.
Genetic Exceptionalism and Willingness to Donate
We did not find associations between genetic exception-
alism and decreased levels of willingness to donate DNA
and medical information in any country; there was either
no association or a positive association (Figure 6). As ex-
pected, there was evidence for heterogeneity (I2 ¼ 70%).
The pooled OR for the association between genetic excep-
tionalism and willingness to donate was 1.60 (95% CI ¼
1.47–1.75).
Trust and Willingness to Donate
In all the samples, apart from India, there was a strong as-
sociation between trust in multiple actors and willingness
to donate DNA and medical information (Figure 7).
Although there was substantial heterogeneity (I2 ¼ 88%),
with the exception of India, this variation was in the
strength of the positive association between trust and dona-
tion rather than the direction of the association. The
pooled OR was 3.85 (95% CI ¼ 3.34–4.44).The AmericaDiscussion
The ‘‘Your DNA, Your Say’’ project is a very large social sci-
ences study conducted on global public attitudes toward
genomic data sharing; it involves a whole mixture of coun-
tries with different health systems, population characteris-
tics, and variation in the availability of genomic technol-
ogy and research. The results show patterns of both
consistency and diversity across the globe. What is striking
is that public willingness to donate data for research is low
across the world; the inclination to trust multiple users
with shared data is also low. The reasons for this are com-
plex and multifaceted.
Genomic research, by its very nature, relies on the ability
to share data between geographical boundaries because no
one single project will unravel the contribution DNA
makes to understanding, predicting, and ultimately treat-
ing disease in ethnically diverse populations. Our findings
highlight how important it is to better focus on familiar-
izing public audiences with the purposes of genomic
research and the reliance of data sharing as part of this.
The field of genomics research depends on members of
the public’s being comfortable for data about them to be
used in research. Although this industry must have exem-
plary models of conduct that make them worthy of public
trust, being able to authentically communicate this is
likely to help increase the willingness of publics to donate
their data. We will explore what publics believe will help
increase the trustworthiness of researchers in future
papers.
Attitudes toward donation are shaped by with whom
data are shared and by whom they are most likely to be
used. Across our sample, people are less willing to donate
data to for-profit users than they are to non-profit organi-
zations or doctors. This echoes prior work in the UK, then Journal of Human Genetics 107, 743–752, October 1, 2020 747
Figure 4. Trust in Donating DNA andMedical Information toMore than One User (Including Doctor, Researcher, Company, Govern-
ment, etc.), Stratified by Country
Each bar shows the percentage of the sample who were or were not willing to donate their DNA and medical information to more than
one recipient (e.g. medical doctors and for-profit researchers).USA, Australia, Egypt, China, and across Europe.7–10,13 In
some countries, notably India but to a lesser extent the
USA, China, and Pakistan, the distinction between non-
profit and for-profit research is less clear-cut. This may
reflect the differing local roles of the private sector in
healthcare and research. In India, for example, studies sug-
gest a preference for private-sector rather than public
healthcare, whereas healthcare in the USA is predomi-
nantly delivered in the private sector.24 The between-coun-
try differences indicate that nuanced approaches, tailor-
made to each cultural setting, are required when explain-
ing data sharing processes.
The variable responses to willingness to donate to multi-
ple users, a situation that most accurately reflects current
research practice, suggests that there is a continuing need
for clearer messages about the collaborative nature of
contemporary genomics research (including the flow of
data that may be accessed by multiple entities multiple
times and for different uses) and the role of partnership be-
tween non-profit and for-profit sectors.25 It also suggests
the need to explore factors that deter people from donating
to for-profit researchers. The overall analysis further iden-
tifies countries, notably Germany and Japan, where partic-
ipants were less willing to donate their DNA and health
data overall—findings which echo previous work on con-
cerns around the use of genetic data.26
We highlight the important role of trust in shaping peo-
ple’s willingness to donate DNA and medical data. In our
analysis, trust is consistently associated with the willing-
ness to donate, albeit with varying strength. This finding
corresponds with our own previous work and prior na-
tional and comparative studies, where available, that
provide evidence for the importance of building trust
through both clarity of purpose and demonstrably
trustworthy technical infrastructures and governance748 The American Journal of Human Genetics 107, 743–752, Octobearrangements.10,12,13,16 However, the varying relationship
between trust and willingness to donate suggests that trust
in data users may not mean the same thing everywhere.27
Further, our findings relate to trust in actors in people’s
own countries, but attitudes to data users outside
one’s own country may be less supportive; this has impli-
cations for the local viability of international research
initiatives.26,28 This suggests the importance of fostering
trust locally through governance regimes that are sensitive
to public expectations and concerns.
We found that those people who are most familiar with
genetics, and particularly those with personal experience
through being a patient, having a family history of an in-
herited condition, or working in the genetics field, are
consistently those most willing to donate their DNA and
health data. Conversely, lack of familiarity with genetics
was associated with reticence about data donation.
Thus, the field of genomics needs to do much more to
explain and invite public debate on the global contribu-
tion genomic research makes toward understanding, pre-
dicting, and ultimately treating disease (i.e., increasing fa-
miliarity with the purpose of genetic research). This
message extends work that has shown that prior engage-
ment is a key factor in shaping willingness to participate
in genetics research.13,26 We also found that there is
consistently low familiarity with the concepts of DNA, ge-
netics, and particularly genomics around the world. In
only Italy and the USA do more people claim to be
familiar than unfamiliar. Previous research has similarly
found that, in the UK for example, only 34% had some
knowledge of genomics.29 In some cases, however, the
level of familiarity we describe is somewhat lower than
has been identified in previous research—particularly in
Japan, possibly because the term ‘‘genome’’ in Japanese
is an English loanword.30r 1, 2020
Figure 5. Forest Plot Displaying Associa-
tion between Willingness to Donate DNA
and Medical Information and Familiarity
with Genomics, Stratified by Level of Famil-
iarity
For each level of familiarity, the forest plot
displays the odds ratio (OR) estimate and
associated 95% confidence interval (CI) for
the sample from each country as a dark
blue box with a horizontal line and the
overall OR and 95% CI across all countries
as a light blue diamond. For each level of fa-
miliarity, the comparator is the ‘‘unfamiliar’’
category.The low level of familiarity suggests a need to recog-
nize challenges associated with communicating genetic
information. However, we should be cautious about
equating familiarity with knowledge and are fully aware
that familiarity is not a proxy measurement for under-
standing. Among our authorship are experienced genetic
counsellors who are cognizant of the importance of help-
ing patients to ‘‘make meaning’’ of the concepts of geno-
mics, for example, by explaining why genetics is relevant
to us in society and what the technology can offer us, as
a priority over explaining the technical scientific con-
cepts, such as DNA’s consisting of four chemical basesThe American Journal of Human G(‘‘knowledge, literacy, understand-
ing’’). This is because we know empir-
ically that publics understand geno-
mics through personal and family
experience in terms that are not
necessarily those of a technical scien-
tific vocabulary.27 Our findings sug-
gest the continued need to consider
how awareness of genomics (as
opposed to literacy or scientific
knowledge) can be useful in making
decisions about genomic data
donation.
Interestingly, diverse responses
were found for the question of ge-
netic exceptionalism. Whether DNA
is similar to or different from other
medical information is a repeated
and contested question in discus-
sions of ethics and law related to ge-
netics.14,15 In line with our previous
work, the findings of the current
study suggest that perceiving genetic
material as exceptional does not
reduce the willingness to donate,
and indeed in many cases, it in-
creases the odds of donation.31
Therefore, in line with our recom-
mendations to increase familiarity
with genetics, a useful place to start
(that may indeed increase willing-ness to engage in research) could be to highlight and
encourage public debate about the differences and sim-
ilarities between genomic and other medical data.
Limitations of Study
The limitations of the study and design have been pub-
lished separately.17 As an exploratory cross-sectional on-
line survey, the study is limited in that it captures intended
behavior at a single time point. This may not translate to
practice, and there is some evidence that people are more
hesitant about hypothetical genetic research than they
are in reality.32,33enetics 107, 743–752, October 1, 2020 749
Figure 6. Forest Plot Displaying Associa-
tion between Willingness to Donate DNA
and Medical Information and Perception
of DNA as Being Different from Other
Medical Data (Genetic Exceptionalism)
The forest plot displays the odds ratio (OR)
estimate and associated 95% confidence in-
terval (CI) for the sample from each coun-
try as a dark blue box with a horizontal
line and the overall OR and 95% CI across
all countries as a light blue diamond.Two sources of potential variability should be noted.
Participants in India and Pakistan completed the survey
differently from other sites, either at a central location
or on a tablet provided by field researchers. This may
have introduced variation in the responses. However,
this variability is outweighed by the value of obtaining
responses from lower resource contexts, which are750 The American Journal of Human Genetics 107, 743–752, October 1, 2020often excluded from research into
public attitudes toward genomics.
Second, although close attention
was paid to creating accurate trans-
lations, translating terms such as ge-
nomics, data, or pseudonymization
relies on the available terms in
each language and the cultural
meanings these terms carry. This
may introduce noise in the data
analysis and requires further investi-
gation. Every translated survey was
also back translated into English;the process of translation and back-translation involved
experts with knowledge of genomics and data sharing
so that decisions could be made about the translations
in relation to construct and content validity. However,
other than an expert view on this, because this is a hy-
pothesis-generating study, no further validation was
possible.Figure 7. Forest Plot Displaying Associa-
tion between Willingness to Donate DNA
and Medical Information and Trust in
Donating DNA and Medical Information
to More than One User
The forest plot displays the odds ratio (OR)
estimate and associated 95% confidence
interval (CI) for the sample from each
country as a dark blue box with a horizon-
tal line and the overall OR and 95% CI
across all countries as a light blue
diamond.
Our results are valuable for tentative conclusions and hy-
potheses but do not indicate views of all people from each
of the countries studied.
Conclusions
The ‘‘Your DNA, Your Say’’ project is a large social sciences
study that provides empirical analysis of the global varia-
tion in public perspectives about genomic data. The results
demonstrate the importance of familiarity and trust in the
collection and sharing of genomic and health data.
We conclude that there are clear messages for policy
makers, genomic researchers, clinicians, and govern-
ments who are implementing genomic research strategies
that use data that cross geographical boundaries. More
needs to be done to familiarize public audiences with
(and create two-way dialogue around) the following:
the purpose of global genomic research and why data
donation and subsequent sharing is integral to this;
why a partnership between doctors, non-profit, and for-
profit industries is necessary; and what the relevance of
genomic technology is to our lives. To support this latter
point, we advocate increasing familiarity with the impli-
cations of genome research and the applications of tech-
nology (as opposed to prioritizing genomic literacy or
knowledge) by using the similarities and differences be-
tween genomic and other health data as a springboard
for these conversations.
Maximizing societal benefits from genomic data in-
volves acknowledging and responding to the factors that
shape the decision to donate DNA across social, cultural,
and legal contexts. Public benefit and the protection of
public interests can only be delivered if clear, transparent,
and authentic information is provided to enable publics to
consider if and why their contribution to a partnership
with researchers is important. The global research commu-
nity not only needs to be worthy of trust by the public, but
also urgent steps need to be taken to communicate this.Data and Code Availability
The full dataset of survey responses has not yet been depos-
ited in a public repository because additional countries are
joining the research and we are waiting to finish recruit-
ment. Once recruitment is completely finished, the full da-
taset will be published at https://www.wgc.org.uk/ethics
and publicly available without restriction for anyone to ac-
cess, download, and analyze.Supplemental Data
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